Next Article in Journal
Recovery of Proteolytic and Collagenolytic Activities from Viscera By-products of Rayfish (Raja clavata)
Next Article in Special Issue
Cyclodepsipeptides from Marine Sponges: Natural Agents for Drug Research
Previous Article in Journal
Marine Pyrrolocarbazoles and Analogues: Synthesis and Kinase Inhibition
Previous Article in Special Issue
A New Polyunsaturated Brominated Fatty Acid from a Haliclona Sponge
Mar. Drugs 2009, 7(4), 787-802; doi:10.3390/md7040787
Article

Towards Commercial Production of Sponge Medicines

,  and *
Received: 19 October 2009; in revised form: 21 November 2009 / Accepted: 27 November 2009 / Published: 2 December 2009
(This article belongs to the Special Issue Bioactive Compounds from Marine Sponges)
View Full-Text   |   Download PDF [271 KB, uploaded 2 December 2009]   |   Browse Figures
Abstract: Sponges can provide potential drugs against many major world-wide occurring diseases. Despite the high potential of sponge derived drugs no sustainable production method has been developed. Thus far it is not fully understood why, when, where and how these metabolites are produced in sponges. For the near future sea-based sponge culture seems to be the best production method. However, for controlled production in a defined system it is better to develop in vitro production methods, like in vitro sponge culture or even better sponge cell culture, culture methods for symbionts or the transfer of production routes into another host. We still have insufficient information about the background of metabolite production in sponges. Before production methods are developed we should first focus on factors that can induce metabolite production. This could be done in the natural habitat by studying the relation between stress factors (such as predation) and the production of bioactive metabolites. The location of production within the sponge should be identified in order to choose between sponge cell culture and symbiont culture. Alternatively the biosynthetic pathways could be introduced into hosts that can be cultured. For this the biosynthetic pathway of metabolite production should be unraveled, as well as the genes involved. This review discusses the current state of sponge metabolite production and the steps that need to be taken to develop commercial production techniques. The different possible production techniques are also discussed.
Keywords: bioactive metabolite; biosynthetic pathway; sponge medicine; sponge culture; cell culture bioactive metabolite; biosynthetic pathway; sponge medicine; sponge culture; cell culture
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Koopmans, M.; Martens, D.; Wijffels, R.H. Towards Commercial Production of Sponge Medicines. Mar. Drugs 2009, 7, 787-802.

AMA Style

Koopmans M, Martens D, Wijffels RH. Towards Commercial Production of Sponge Medicines. Marine Drugs. 2009; 7(4):787-802.

Chicago/Turabian Style

Koopmans, Marieke; Martens, Dirk; Wijffels, Rene H. 2009. "Towards Commercial Production of Sponge Medicines." Mar. Drugs 7, no. 4: 787-802.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert